PMID- 28785772
OWN - NLM
STAT- MEDLINE
DCOM- 20171128
LR  - 20220330
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 193
IP  - 12
DP  - 2017 Dec
TI  - Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk 
      of acute toxicities.
PG  - 1024-1030
LID - 10.1007/s00066-017-1188-8 [doi]
AB  - BACKGROUND: Low-dose total skin electron beam therapy (TSEBT) is attracting 
      increased interest for the effective palliative treatment of primary cutaneous 
      T‑cell lymphoma (pCTCL). In this study, we compared toxicity profiles following 
      various radiation doses. PATIENTS AND METHODS: We reviewed the records of 
      60 patients who underwent TSEBT for pCTCL between 2000 and 2016 at the University 
      Hospital of Munster. The treatment characteristics of the radiotherapy (RT) 
      regimens and adverse events (AEs) were then analyzed and compared. RESULTS: In 
      total, 67 courses of TSEBT were administered to 60 patients. Of these patients, 
      34 (51%) received a standard dose with a median surface dose of 30 Gy and 
      33 patients (49%) received a low dose with the median surface dose of 12 Gy 
      (7 salvage low-dose TSEBT courses were administered to 5 patients). After 
      a median follow-up of 15 months, the overall AE rate was 100%, including 
      38 patients (57%) with grade 2 and 7 (10%) with grade 3 AEs. Patients treated 
      with low-dose TSEBT had significantly fewer grade 2 AEs than those with 
      conventional dose regimens (33 vs. 79%, P < 0.001). A lower grade 3 AE rate was 
      also observed in patients who had received the low-dose regimen compared to those 
      with the conventional dose regimens (6 vs. 15%, P = 0.78). Multiple/salvage 
      low-dose TSEBT courses were not associated with an increased risk of acute AEs. 
      CONCLUSION: Low-dose TSEBT regimens are associated with significantly fewer 
      grade 2 acute toxicities compared with conventional doses of TSEBT. 
      Repeated/Salvage low-dose TSEBT, however, appears to be tolerable and can even be 
      applied safely in patients with cutaneous relapses.
FAU - Kroeger, Kai
AU  - Kroeger K
AD  - Department of Radiation Oncology, University Hospital of Muenster, 
      Albert-Schweitzer-Strasse 33 (Albert-Schweitzer-Campus 1, Building A1), 48149, 
      Muenster, Germany.
FAU - Elsayad, Khaled
AU  - Elsayad K
AD  - Department of Radiation Oncology, University Hospital of Muenster, 
      Albert-Schweitzer-Strasse 33 (Albert-Schweitzer-Campus 1, Building A1), 48149, 
      Muenster, Germany. Khaled.elsayad@uni-muenster.de.
FAU - Moustakis, Christos
AU  - Moustakis C
AD  - Department of Radiation Oncology, University Hospital of Muenster, 
      Albert-Schweitzer-Strasse 33 (Albert-Schweitzer-Campus 1, Building A1), 48149, 
      Muenster, Germany.
FAU - Haverkamp, Uwe
AU  - Haverkamp U
AD  - Department of Radiation Oncology, University Hospital of Muenster, 
      Albert-Schweitzer-Strasse 33 (Albert-Schweitzer-Campus 1, Building A1), 48149, 
      Muenster, Germany.
FAU - Eich, Hans Theodor
AU  - Eich HT
AD  - Department of Radiation Oncology, University Hospital of Muenster, 
      Albert-Schweitzer-Strasse 33 (Albert-Schweitzer-Campus 1, Building A1), 48149, 
      Muenster, Germany.
LA  - eng
PT  - Journal Article
TT  - Niedrigdosis-Ganzhautelektronenbestrahlung bei Patienten mit kutanen Lymphomen : 
      Minimales Risiko fur akute Toxizitaten.
DEP - 20170807
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Electrons/*therapeutic use
MH  - Female
MH  - Germany/epidemiology
MH  - Humans
MH  - Lymphoma, T-Cell, Cutaneous/*epidemiology/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Radiodermatitis/epidemiology/*prevention & control
MH  - Radiotherapy Dosage
MH  - Radiotherapy, High-Energy/*statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Salvage Therapy/statistics & numerical data
MH  - Skin Neoplasms/*epidemiology/pathology/*radiotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse effects
OT  - Palliative care
OT  - Radiotherapy
OT  - Recurrence
OT  - Salvage therapy
EDAT- 2017/08/09 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/08/09 06:00
PHST- 2017/04/26 00:00 [received]
PHST- 2017/07/14 00:00 [accepted]
PHST- 2017/08/09 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/08/09 06:00 [entrez]
AID - 10.1007/s00066-017-1188-8 [pii]
AID - 10.1007/s00066-017-1188-8 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2017 Dec;193(12):1024-1030. doi: 10.1007/s00066-017-1188-8. 
      Epub 2017 Aug 7.